Skip to main content
SpringerLink
Log in

Trastuzumab emtansine as second-line therapy for HER2-positive breast cancer: improved survival at high cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Zhang H, et al. Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China. Clinical Drug Investigation : 20 Apr 2021. Available from: URL: https://doi.org/10.1007/s40261-021-01035-4

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trastuzumab emtansine as second-line therapy for HER2-positive breast cancer: improved survival at high cost. PharmacoEcon Outcomes News 877, 24 (2021). https://doi.org/10.1007/s40274-021-7673-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7673-4

Search

Navigation